← Back to Calendar
Live Company Data
NMS
Updated
1m ago
· Data: FMP
Current Price
$276.44
+615.05%
+$237.78 today
Day: $271.94 – $296.00
52-Week Range
Current price is at 76% of 52-week range
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.
Indication
Q1 2026 earnings + ulixacaltamide + relutrigine PDUFA updates
Key Notes
Q1 2026 earnings expected ~May 7, 2026. Dual NDA company with two drugs in FDA review simultaneously — highly unusual. Key updates: FDA acceptance and PDUFA date for ulixacaltamide (ET); relutrigine (DEEs) status update ahead of Sept 27 PDUFA; commercial build progress; $1.5B cash runway. Two potential launches in 2026 make PRAX a top-watched neuroscience name.
⚠️ Not Investment Advice: This information is provided for educational purposes only.
PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period,
issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on
historical base rates and do not account for drug-specific factors. Always consult a financial advisor
before making investment decisions.
Discussion
Share your analysis, research, or questions about this catalyst. No account required.